PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 30, 2026International Journal of Infectious Diseases1 citationsOpen Access

Clindamycin demonstrates clinical effectiveness for bacteremic M1UK Streptococcus pyogenes pneumonia: A case report and in vitro evidence of notable antitoxin effects on M1UK

MEMasayoshi EzakiTNTien Manh NguyenHKHitoshi Kawasuji

Key Points

  • To evaluate the effectiveness of clindamycin in treating bacteremic M1UK Streptococcus pyogenes pneumonia.
  • Reported a case of an immunocompetent patient with bacteremic pneumonia treated with clindamycin.
  • Conducted in vitro tests to assess clindamycin's effect on streptococcal pyrogenic exotoxin A expression in M1UK and M1global strains.
  • Clindamycin improved the clinical condition of the patient.
  • In vitro tests showed clindamycin suppressed speA expression in M1UK strains but not in M1global strains.
  • Levofloxacin did not demonstrate a suppressive effect on exotoxin expression.

Abstract

We report a case of bacteremic M1UK Streptococcus pyogenes pneumonia in an immunocompetent patient, which improved with adjunctive clindamycin therapy.In vitro, clindamycin consistently suppressed expression of streptococcal pyrogenic exotoxin A (speA) in M1UK strains but not in the M1global strain, whereas levofloxacin showed no suppressive effect.These findings support a potential antitoxin role of clindamycin in M1UK infections.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ezaki et al. (2026) studied this question.

synapsesocial.com/papers/69f2f0e31e5f7920c6386ee7https://doi.org/10.1016/j.ijid.2026.108742
Ask AI
Helpful
Bookmark
Share
View Full Paper